Newsletters


Filter by volume

Agenus on Twitter

FDA clears IND application for natural killer T-cell therapy @Agenus_Bio @Agentus_CellTX to treat #COVID19 - phase 1 trial to come bit.ly/2Ax2Rwscome bit.ly/2 Retweeted by Agenus Inc. ($AGEN)

FBR has informed callers to use 973-413-6102 twitter.com/Agenus_Bio/sta…

EXPERT PANEL TONIGHT! Join Dr. Steven @ODayMD @JohnWayneCI, Dr. Chuck Drake @nyphospital & @columbiacancer, & Dr. Jennifer Buell from @Agenus_Bio to discuss Next Generation IO Therapies, including AGEN1181 with Mayank Mamtani from @BRileyFinancial #innovation #nextgeneration

test Twitter Media - EXPERT PANEL TONIGHT!  Join Dr. Steven @ODayMD  @JohnWayneCI, Dr. Chuck Drake @nyphospital & @columbiacancer, & Dr. Jennifer Buell from @Agenus_Bio to discuss Next Generation IO Therapies, including AGEN1181 with Mayank Mamtani from @BRileyFinancial  #innovation #nextgeneration https://t.co/omgnBDFffg

$AGEN will host calls with investors to address your questions every Wednesday @4PM. To register, please call 781-674-4408. Retweeted by Agenus Inc. ($AGEN)

Proud to be leading the charge with @Agenus_Bio and my oncology colleagues with a next generation CTLA-4 antibody. twitter.com/jbuell01/statu… Retweeted by Agenus Inc. ($AGEN)

$AGEN sends special thanks to our AGEN1181 PIs & staff for your excellent care & continued accrual during this difficult #COVID19 pandemic: Dr. @ODayMD @JohnWayneCI; Dr El-Khouiery @USC; Dr. Gordon @HonorHealth; Dr. Bullock @BIDMChealth; Dr. Ramamurthy @UTHealthcareSA #ASCO2020

test Twitter Media - $AGEN sends special thanks to our AGEN1181 PIs & staff for your excellent care & continued accrual during this difficult #COVID19 pandemic:  Dr. @ODayMD @JohnWayneCI; Dr El-Khouiery @USC; Dr. Gordon @HonorHealth; Dr. Bullock @BIDMChealth; Dr. Ramamurthy @UTHealthcareSA #ASCO2020 https://t.co/C0AUb2LDTg

Agenus NEWSLETTER: Paulo Moriera leads path-breakers: advancing 14 new discoveries to clinic with FIM 2.5x faster than industry & readiness for 2 planned BLA filings in 2020. READ MORE: agenusbio.com/wp-content/upl…

test Twitter Media - Agenus NEWSLETTER:  Paulo Moriera leads path-breakers: advancing 14 new discoveries to clinic with FIM 2.5x faster than industry & readiness for 2 planned BLA filings in 2020. READ MORE: https://t.co/s2CWvuDPik https://t.co/FeHEFMuYjM

@beilis_jay @jbuell01 The replay will also be available on our website after the discussion: investor.agenusbio.com/presentation-w…

Join @Agenus_Bio at #RBCHealthcare2020 at 1:20PM when our President & COO Dr. Jennifer Buell (@jbuell01) will meet with Biotech Analyst Dr. Gregory Renza on Beyond 2020: The Changing Face of Healthcare.

test Twitter Media - Join @Agenus_Bio at #RBCHealthcare2020 at 1:20PM when our President & COO Dr. Jennifer Buell (@jbuell01) will meet with Biotech Analyst Dr. Gregory Renza on Beyond 2020: The Changing Face of Healthcare. https://t.co/hvB24aO5iN

FDA Clears AgenTus IND for Allogeneic iNKT Cell Therapy - May 13, 2020 investor.agenusbio.com/2020-05-13-FDA…

$AGEN will host calls with investors to address your questions every Wednesday @4PM. To register, please call 781-674-4408.

Agenus First Quarter Update: AGEN1181+/- bali (PD-1) benefits 70% in P1; Bali/Zali combo shows 26% ORR (n=55); Two INDs filed for allogeneic iNKTs in cancer & COVID-19; Two TIGITs advancing to IND; structured to reduce burn ~$50 investor.agenusbio.com/2020-05-07-Age…

$AGEN Fc enhanced #TIGIT outperforms tested competitors (#AACR2019) & novel TIGIT bispecific shows potent tumor killing in difficult to treat CRC model. Both headed to clinic 1H21. #Immunotherapy agenusbio.com/wp-content/upl… Retweeted by Agenus Inc. ($AGEN)

NEWSLETTER: Two $AGEN TIGIT antibodies on track to enter clinic in 1H 2021. READ MORE: agenusbio.com/wp-content/upl…

test Twitter Media - NEWSLETTER:  Two $AGEN TIGIT antibodies on track to enter clinic in 1H 2021.  READ MORE: https://t.co/MRqJZqHgqO https://t.co/y3etuZu4C7

$AGEN will host calls with investors to address your questions every Wednesday @4PM. To register, please call 781-674-4408.

.@armish, together we are a formidable force. twitter.com/armish/status/…

$AGEN NEXT NEWSLETTER (May 5) highlights @Agenusbio TIGIT(s). Why the excitement? What are optimal combos? Learn more about our novel TIGIT programs with superior pre-clinical tumor killing as monotherapy in PD-1 combo. #TIGIT #Immunotherapy agenusbio.com/wp-content/upl…